Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including astrocytes; strongest in epididymal principal cells | 0.75 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 6 pathways; mostly growth signalling | 0.60 |
Knock down and overexpress MAPK12 in astrocytes; measure phospho-ERK and phospho-AKT response to GDNF and α-synuclein uptake and degradation, and dopamine neuron survival in co-culture.
- Cell type
- astrocytes
- Direction
- Both arms: public data does not say which way helps.
- Molecular readout
- phospho-ERK and phospho-AKT response to GDNF
- Functional readout
- α-synuclein uptake and degradation, and dopamine neuron survival in co-culture
- Rule-out
- If neither arm moves phospho-ERK by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of MAPK12 in iPSC-derived midbrain astrocytes; n = 3 differentiations; readouts: phospho-ERK and phospho-AKT response to GDNF; α-synuclein uptake and degradation, and dopamine neuron survival in co-culture. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- MAPK12 in dopamine neurons, braak-0.39 (p 0.300) → -0.15 (p 0.697)receipt 14116
- MAPK12 in astrocytes, braak-0.08 (p 0.840) → +0.05 (p 0.893)receipt 14115
Swarm cases
receipt 14116: MAPK12 in dopamine neurons, braak
- power
- full sample -0.31 (p 0.204, n 18), 95% CI -0.68 to +0.18. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.32 (p 0.201, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.47 (p 0.050, n 18). not the mix.
- skeptic
- leave-one-out range -0.46 to -0.23, sign flips 0; without severely affected donors -0.31 (p 0.204, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MAPK12 in dopamine neurons.
case closed: nothing better to follow up.
receipt 14115: MAPK12 in astrocytes, braak
- power
- full sample -0.04 (p 0.881, n 18), 95% CI -0.50 to +0.44. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.01 (p 0.976, n 18). does not hold up.
- composition
- astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.07 (p 0.787, n 18). could be the mix.
- skeptic
- leave-one-out range -0.16 to +0.08, sign flips 4; without severely affected donors -0.04 (p 0.881, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MAPK12 in astrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts